Treatment of patients with refractory chronic lymphocytic leukemia with alemtuzumab, alone or in combination with fludarabine
https://doi.org/10.17650/1818-8346-2011-6-2-4-7
Abstract
In present study the immediate and long-term therapy results of 14 patients with refractory chronic lymphocytic leukemia (CLL) are analyzed. Treatment program included alemtuzumab alone or in combination with fludarabine.
About the Authors
E. V. Kataeva
M.F. Vladimirsky Moscow Regional Research Clinical Institute
Russian Federation
Russian Federation
A. K. Golenkov
M.F. Vladimirsky Moscow Regional Research Clinical Institute
Russian Federation
Russian Federation
E. V. Trifonova
M.F. Vladimirsky Moscow Regional Research Clinical Institute
Russian Federation
Russian Federation
G. A. Dudina
M.F. Vladimirsky Moscow Regional Research Clinical Institute
Russian Federation
Russian Federation
T. A. Mitina
M.F. Vladimirsky Moscow Regional Research Clinical Institute
Russian Federation
Russian Federation
L. L. Vysotskaya
M.F. Vladimirsky Moscow Regional Research Clinical Institute
Russian Federation
Russian Federation
T. D. Lutskaya
M.F. Vladimirsky Moscow Regional Research Clinical Institute
Russian Federation
Russian Federation
I. V. Buravtsova
M.F. Vladimirsky Moscow Regional Research Clinical Institute
Russian Federation
Russian Federation
R. V. Gorenkov
M.F. Vladimirsky Moscow Regional Research Clinical Institute
Russian Federation
Russian Federation
Yu. Yu. Chuksina
M.F. Vladimirsky Moscow Regional Research Clinical Institute
Russian Federation
Russian Federation
V. V. Yazdovskiy
M.F. Vladimirsky Moscow Regional Research Clinical Institute
Russian Federation
Russian Federation
References
1. Rai K.R., Peterson B.L., Appelbaum F.R. et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000;343:1750–7.
2. Leporrior M., Chevret S., Cazin B. et al. Randomized comparison of fludarabin, CAP and CHOP in 938 previously untreatedstage B and C chronic lymphocytic leukemia patients. Blood 2001;98(23):2319–25.
3. Catovsky D., Richard S., Matutes E. et al. Assesment of fludarabin plus cyclophosphamide for patients with chronic lymphocytic leukemia. Lancet 2007;270:230–9.
4. Hallek M., Fingerle-Rowson G., Fink A.M. et al. Immunochemotherapy with fludarabine (F), cyclophosphamide (C) and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) impruves responses rates and progression-freesurvival (PFS) of previously untreated patients with advanced chronic lymphocytic leukemia. Blood 2008;112:325.
5. Hillmen P., Skotnicki A.B., Robak T. et al. Alemtuzumab compared with chlorambucil as fist-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007;2:5616–23.
6. Kennedy B., Raustron A., Carter C. et al. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood 2002;99:2245–7.
7. Elter T., Borchmann P., Schultz H. et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractoryB-cell chronic lymphocytic leukemia: result of a phase II trial. J Clin Oncol 2005;23:7024–31.
8. Hallek M., Cheson B.D., Catovsky D. et al. Guidelines for the diagnosis and treatment of chronic ymphocytic leukemia: a report from the Internaional Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute- Working Group 1996 guidelines. Blood 2008;111:5446–56.
Review
For citations:
Kataeva E.V., Golenkov A.K., Trifonova E.V., Dudina G.A., Mitina T.A., Vysotskaya L.L., Lutskaya T.D., Buravtsova I.V., Gorenkov R.V., Chuksina Yu.Yu., Yazdovskiy V.V. Treatment of patients with refractory chronic lymphocytic leukemia with alemtuzumab, alone or in combination with fludarabine. Oncohematology. 2011;6(2):4-7. (In Russ.) https://doi.org/10.17650/1818-8346-2011-6-2-4-7
Views:
9782
Email this article 